Genfit SA Expands R&D, Gains FDA Approval
Company Announcements

Genfit SA Expands R&D, Gains FDA Approval

Genfit SA (GNFT) has released an update.

Genfit SA, a leader in liver disease research, has expanded its R&D portfolio, focusing on Acute-on-Chronic Liver Failure (ACLF) and other serious liver diseases. The company has successfully received FDA accelerated approval for Iqirvo®/elafibranor for Primary Biliary Cholangitis (PBC) and continues to advance its diagnostic and therapeutic programs. Genfit, headquartered in Lille, France, operates globally with key offices in Switzerland and the USA, and is publicly traded on Nasdaq and Euronext.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit’s Revenue Surge Driven by Key Milestone
TipRanks Auto-Generated NewsdeskGenfit’s Iqirvo Wins EU Approval for Liver Condition
TipRanks Auto-Generated NewsdeskGENFIT SA Showcases Robust 2024 Financial Health
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App